Bimzelx, which is already authorised in the UK to treat certain patients with plaque psoriasis, is now the first treatment available for PsA and axSpA that is designed to inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory disease.
NICE’s guidance follows a recent approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and was expedited through the institute’s proportionate approach to the technology appraisal pathway, which allows eligible patients to access Bimzelx earlier than under the routine approval processes.
PsA and axSpA are two forms of chronic inflammatory arthritis, affecting over 800,000 people in the UK combined…
